Cl.CN(C)CCCN=C=NCC.[Cl:13][C:14]1[S:18][C:17]([C:19]([N:21]2[CH2:25][CH:24]([C:26]([OH:28])=O)[O:23][CH2:22]2)=[O:20])=[CH:16][CH:15]=1.[NH2:29][C:30]1[CH:35]=[CH:34][C:33]([N:36]2[CH2:41][CH2:40][O:39][CH2:38][C:37]2=[O:42])=[CH:32][CH:31]=1.C(=O)([O-])O.[Na+]>CN(C)C=O>[O:42]=[C:37]1[CH2:38][O:39][CH2:40][CH2:41][N:36]1[C:33]1[CH:32]=[CH:31][C:30]([NH:29][C:26]([CH:24]2[O:23][CH2:22][N:21]([C:19]([C:17]3[S:18][C:14]([Cl:13])=[CH:15][CH:16]=3)=[O:20])[CH2:25]2)=[O:28])=[CH:35][CH:34]=14.2 479 mg (2.50 mmol) of N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide hydrochloride (DAPECI) are added to a solution of 500 mg (1.91 mmol) of 3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxylic acid and 367 mg (1.91 mmol) of 4-(4-aminophenyl)morpholin-3-one in 5 ml of dimethylformamide (DMF), and the mixture is stirred at room temperature for 18 hours. The reaction mixture is added to saturated sodium hydrogencarbonate solution, and the precipitate formed is filtered off, giving N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide (“A5”) as a colourless solid; ESI 436.